ArticleCurrent cardiology reviews2021
The Utility of Circulating and Imaging Biomarkers Alone and in Combination in Heart Failure.
Article in Current cardiology reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Amino Acid-Derived Metabolic Signature Across Stages of Systolic Dysfunction: Derivation and Internal Evaluation of the HASI (Heart Failure Amino Acid-Derived Systolic Index)-40 Index.International journal of molecular sciences · 2026Article
- Monitoring high-risk patients for chemotherapy-related cardiotoxicity: A retrospective analysis.World journal of clinical cases · 2025Article
- Heart Failure Paradigms in the Developed World - A Reflection - Part 1Current cardiology reviews · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical trials in the treatment of heart failure have relied on the use of a composite of hard clinical endpoints to evaluate the efficacy of the treatment arm. This has led to prolonged trials requiring large patient cohorts and extensive funding to reach statistical significance. In this paper, we have explored the potential of currently available circulating and imaging biomarkers associated with heart failure as a surrogate for hard clinical end points in clinical trials. This would be expected to result in shorter trials, smaller patient cohorts and limited funding required. We have subsequently theorized on combining circulating and imaging biomarkers as a surrogate for clinical end points such as hospitalization from heart failure and cardiac mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.